India’s Aurobindo Pharma has announced that it has received approval to market risperidone and alendronate, used to treat schizophrenia and osteoporosis respectively, in the Australian market.

Aurobindo Pharma Australia gained the approval from the country’s Therapeutic Goods Administration to register the tablets, which should be taken orally.

Alendronate and risperidone were approved by the US Food and Drug Administration in 2008 and 2009 respectively.

Risperidone products are worth nearly $27.5m in Australia, while the market for alendronate was worth $14m for the 12 months ending September 2010, according to IMS data.